Spersacarpine Sterile Eye
Every registration of this product has been cancelled.
(3S,4R)-3-Ethyl-4-[(3-methylimidazol-4-yl)methyl]oxolan-2-one
Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 5910.
Registration
- Applicants
- 1
- Registrations
- 4
Applicants and registrations
| Applicant | Brands | Dosages | Registrations | Schedule | Leaflets |
|---|---|---|---|---|---|
| The Premier Pharmaceutical Co LtdCancelled | Spersacarpine sterile eye | 1 %, 2 %, 3 %, 4 % | H1279, H1280, H1281, H1282 | Not determined | None |
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Spersacarpine 1 % sterile eye drops EACH 100 ml CONTAINS PILOCARPINE A 1,0 g | 1 %Drops | H1279 | Cancelled | Not determined | None |
| Spersacarpine 4 % sterile eye drops EACH 100 ml CONTAINS PILOCARPINE A 4,0 g | 4 %Drops | H1280 | Cancelled | Not determined | None |
| Spersacarpine 2 % sterile eye drops EACH 100 ml CONTAINS PILOCARPINE A 2,0 g | 2 %Drops | H1281 | Cancelled | Not determined | None |
| Spersacarpine 3 % sterile eye drops EACH 100 ml CONTAINS PILOCARPINE A 3,0 g | 3 %Drops | H1282 | Cancelled | Not determined | None |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
Listings for this ingredient that could not be applied to this product
S4: Pilocarpine
- except ophthalmic preparations thereof intended for glaucoma.
Consolidated Schedules 06 July 2026, line 7562
S3: Pilocarpine
- ophthalmic preparations thereof intended for glaucoma.
Consolidated Schedules 06 July 2026, line 4126
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
SAHPRA has not published a professional information or patient information leaflet for this product.